Sponsors (7)
Creates an overseas FDA presence that could improve safety, market access, and international coordination, but it requires taxpayer funding, raises diplomatic/security complexities, and risks diverting FDA resources from domestic oversight.
Patients and hospitals benefit from fewer unsafe or poor-quality imported medical products because foreign manufacturers would adopt FDA-conforming good manufacturing practices.
U.S. exporters and biopharma firms gain clearer regulatory pathways and better FDA feedback, potentially easing market entry and collaboration with Abraham Accords countries.
Strengthening regulatory partners abroad could improve public-health surveillance and emergency coordination, supporting faster cross-border responses to product-safety and health incidents.
FDA staff and resources assigned overseas could divert attention and capacity from domestic regulatory oversight, potentially weakening U.S. domestic monitoring of medical products.
Placing an overseas FDA office in a foreign country may raise diplomatic and security costs and operational complexity, requiring additional coordination with U.S. security recommendations.
Establishing and staffing a new overseas FDA office will require taxpayer funding for setup and ongoing operations, with no specific appropriation specified.
Based on analysis of 2 sections of legislative text.
Creates an FDA office in an Abraham Accords country to give technical assistance, promote regulatory convergence (including GMP), and share U.S. regulatory information.
Introduced March 3, 2025 by Diana Harshbarger · Last progress March 3, 2025
Creates an "Abraham Accords Office" inside the Food and Drug Administration to be located in an Abraham Accords country and led by a director. The office will be staffed by FDA personnel and must be established and located within two years; it will give technical assistance, help align regulatory requirements (including good manufacturing practices), and share information about U.S. regulatory pathways with partner regulators. The HHS Secretary must report to Congress within three years on progress, counts of partners assisted, and recommendations to improve coordination.